|Day Low/High||34.83 / 34.99|
|52 Wk Low/High||33.97 / 46.47|
Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 R ivipansel (GMI-1070): E valuating S afety, E fficacy and T ime to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints.
Pfizer Inc. (NYSE: PFE) today announced the closing of its joint venture with GlaxoSmithKline plc (NYSE: GSK) to combine the parties' respective consumer healthcare businesses to create the world's largest over-the-counter (OTC) business with robust...
Stocks decline Tuesday as investors digest a plate full of earnings reports, the start of the two-day Fed meeting, and President Trump's remarks doubting the success of U.S. trade talks with China.
Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc.
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
Pfizer reports earnings and announces a massive tie-up with Mylan, sending shares of the latter shooting higher.
What new management means for Mylan shareholders moving forward.
Jim Cramer weighs in on Pfizer and Mylan, Starbucks and, of course, the causes for a week of market madness.
Mylan and Pfizer agreed to combine their off-patent drug businesses in an all-stock deal that will create a new company based in the United States.
Jim Cramer tackles Starbucks, the Federal Reserve, earnings and Mylan ahead of a week filled with potentially market-moving headlines.
Pfizer is in talks to merge its off-patent drug operation with Mylan.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.
Due to today's announcement of a proposed transaction between Pfizer and Mylan, Pfizer's second-quarter 2019 earnings conference call with investment analysts has been rescheduled for today, July 29, 2019, at 10:30 a.
Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2019 and updated certain components of its 2019 financial guidance.
- Delivers enhanced global scale and geographic reach, including leading positions in China and other emerging markets
Mylan shares were indicated sharply higher Monday amid reports the generic drugs group is set to create a separate business with Pfizer for off-patent pharmaceuticals.
Shareholders of Mylan would get around 40% of the newly formed business and Pfizer shareholders would get the remaining 60%, according to Reuters.
Jim Cramer says higher sales, higher prices, and demand from emerging markets seem to be fueling a return to the days of great senior growth stocks.
Jim Cramer weighs in on Pfizer, eBay, Cloudera, Cadence Systems, CRISPR Therapeutics, Moderna, Tandem Diabetes Care, and more.
Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.
Pfizer Inc. (NYSE:PFE) today announced the United States (U.
The Dow & S&P 500 closed at record highs with the S&P barely missing ending the day above 3,000.
Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?
Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.